 | |
| Names | |
|---|---|
| IUPAC name (2R)-2-[[(2R)-2-[[2-[[2-[[(2R)-2-amino-3- | |
| Other names [Leu]enkephalin; [Leu5]enkephalin; | |
| Identifiers | |
3D model (JSmol) | |
| ChEBI | |
| ChEMBL | |
| ChemSpider |
|
| ECHA InfoCard | 100.055.852 |
| UNII | |
| |
| |
| Properties | |
| C28H37N5O7 | |
| Molar mass | 555.62 g/mol[1] |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Leu-enkephalin is anendogenousopioid peptideneurotransmitter with theamino acid sequence Tyr-Gly-Gly-Phe-Leu that is found naturally in the brains of many animals, including humans.[2][3] It is one of the two forms ofenkephalin; the other ismet-enkephalin.[2] Thetyrosine residue at position 1 is thought to be analogous to the 3-hydroxyl group onmorphine.[4] Leu-enkephalin hasagonistic actions at both theμ- andδ-opioid receptors, with significantly greater preference for the latter. It has little to no effect on theκ-opioid receptor.[5][6]
Anasal sprayformulation of leu-enkephalin (developmental code names NES-100, NM-0127, NM-127, PES-200; proposed brand name Envelta) is under development by Virpax Pharmaceuticals for the treatment ofpain andpost-traumatic stress disorder (PTSD).[7] As of November 2023, it is up to thepreclinical stage of development for these indications.[7]
.svg) | Thisbiochemistry article is astub. You can help Wikipedia byexpanding it. |
